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MetalloproteinasePodocyteTRPC6 channels have been implicated in glomerular diseases. Syndecan-4 (Sdc4) is a membrane pro-
teoglycan that can be cleaved to release a soluble ectodomain capable of paracrine and autocrine signaling. We
have conﬁrmed that overexpression of Sdc4 core protein increases surface abundance of TRPC6 channels in cul-
tured podocytes, whereas Sdc4 knockdown has the opposite effect. Exposure to soluble Sdc4 ectodomain also in-
creased the surface abundance of TRPC6, and increased cationic currents evoked by a diacylglycerol analog in
podocytes. Sdc4 ectodomain increased generation of reactive oxygen species (ROS), reduced activation of
RhoA, increased activation of Rac1, increased nuclear abundance of NFATc1, and increased total β3-integrin.
The effects of Sdc4 ectodomain on cell-surface TRPC6 were blocked by the ROS quencher TEMPOL, and by the
Rac1 inhibitor NSC-23766, but were not blocked by inhibition of calcineurin–NFATc1 signaling. The Sdc4 core
protein co-immunoprecipitates with β3-integrin in cultured podocytes. Moreover, effects of Sdc4 ectodomain
on TRPC6, ROS generation, Rac1 and RhoA modulation, and NFATc1 activation were blocked by cilengitide, a se-
lective inhibitor of outside-in signaling through αv-containing integrins. Exposure to TNF, or serum from three
patients with recurrent FSGS in relapse, increased shedding of podocyte Sdc4 ectodomains into the surrounding
medium. This was also observed after treating podocytes with the metalloproteinase ADAM17 or after overex-
pression of the Sdc4 core protein. Increased concentrations of Sdc4 ectodomain were detected in urine of rats
during acute puromycin aminonucleoside nephrosis. Locally generated Sdc4 may play a role in regulating
TRPC6 channels, and may contribute to glomerular pathology.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Podocytes are complex stellate cells that attach to the external sur-
face of glomerular capillaries, inside Bowman's capsule, where they
form an essential component of the glomerular ﬁltration apparatus
[1]. The foot processes of podocytes, from which these cells get their
name, extend at regular intervals from major processes. Their basaltalloproteinase 17; Ang II,
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), hroshanr@Central.UH.EDUdomains attach to the subjacent glomerular basement membrane
(GBM) and cover the entire external capillary surface. Adjacent foot
processes emanating from different major processes adhere to each
other in an interdigitating pattern. The ectodomains of specialized ad-
hesion molecules, including nephrin and Neph1, form a porous matrix
between the adjacent foot processes. These junctions, known as slit di-
aphragms, are an essential component of the permselective glomerular
ﬁlter. Distension of the glomerular capillary and hydrodynamic ﬂow
through the slit diaphragm subjects podocytes to considerable forces
that can cause podocytes to detach from the GBM, for example as a re-
sult of glomerular hypertension or hyperﬁltration [2]. Loss of podocytes
is amajor problembecause there is a very limited capacity for these cells
to be replaced [1].
Podocytes are not static structures. Under certain conditions the foot
processes will broaden and retract back into themajor processes, a pro-
cess known as effacement. At least the initial stages of foot process
effacement are reversible [3], and may represent an adaptation to pre-
vent podocyte detachment in response to hydrodynamic and shear
forces, or exuberant cell growth [2]. Effacement requires major changes
in the dynamics of the foot process cytoskeleton, which can occur in a
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ment is overexpression or gain of function of TRPC6 channels in
podocytes. This was initially inferred from analyses of patients with
gain-of-function mutations of TRPC6 channels [4,5], and subsequently
in transgenic mice that selectively overexpress TRPC6 channels in
podocytes [6]. Sustained hyperactivation of TRPC6 eventually results
in loss of podocytes, resulting in focal glomerulosclerosis. Moreover,
elevated expression of TRPC6 is observed in several acquired forms of
glomerular diseases [7].
TRPC6 channels are Ca2+-permeable cation channels that are
expressed in several parts of the podocyte, including the slit diaphragm
domains of foot processes [8], and in the major processes and cell body
[9]. Podocyte TRPC6 channels become active in response to various G
protein signaling cascades, including pathways activated by angiotensin
II (Ang II) [10,11] andATP [12]. Activation of TRPC6 in those cascades re-
quires generation of reactive oxygen species (ROS) [10–12], which also
occurs in response to insulin [13] or after application of canonical lipid
activators of TRPC6 such as diacylglycerol (DAG) [14].
A recent study has shown that the heparin sulfate proteoglycan
syndecan-4 (Sdc4) can interact with TRPC6 and facilitate its expression
and trafﬁcking to the cell surface in podocytes [15]. Sdc4 canbedetected
in many cell types, including glomerular endothelial cells [16] and
podocytes [17]. Sdc4 is inserted into the plasma membrane as a type-
1 single-pass core protein [18,19]. Sdc4 dimers can function as adhesion
proteins or as a receptors or co-receptors for other ligands, such asﬁbro-
blast growth factors, vascular endothelial growth factors, and platelet-
derived growth factors [19,20]. Sdc4 forms higher order oligomers
upon binding of certain extracellular ligands, resulting in movement
of these proteins into lipid raft domains [20]. The intracellular domains
of Sdc4 can interact with numerous binding partners, including α-
actinin [21], various forms of protein kinase C [22], and modulators of
small GTPases [23,24]. This can lead to changes in membrane rufﬂing
andmigration [24], modulation of focal adhesions and actin stressﬁbers
[19,25,26] and endocytosis of integrins [27].
In addition, the ectodomain of Sdc4 can be cleaved by various matrix
metalloproteinases and other sheddases, a process that can be enhanced
in response to various extracellular signals [28]. Sdc4 ectodomain shed-
ding results in formation of a soluble and diffusible signaling molecule
that can act as an autocrine or paracrine effector, or as a competitive in-
hibitor of the intact core proteoglycan [29,30].
In thepresent study,we have studiedmodulation of podocyte TRPC6
channels by Sdc4 in more detail. We have conﬁrmed earlier reports
showing that the Sdc4 core protein is required for normal expression
of TRPC6 in these cells, and we show that the core protein immunopre-
cipitates with β3-integrin. In addition, we show that exposure to the
Sdc4 ectodomain is sufﬁcient to modulate TRPC6 channels, as well as
the activities of RhoA and Rac1 and the generation of ROS. In addition,
we show that outside-in signaling through integrins is required for
TRPC6 regulation by Sdc4 ectodomains. Finally, we show that circulat-
ing factors relevant to glomerular diseases increase shedding of the
Sdc4 ectodomain from cultured podocytes into the surrounding medi-
um, and that increased Sdc4 ectodomain can be detected in the urine
in a rat model of podocyte disease.
2. Materials and methods
2.1. Cell lines, siRNAs, and expression vectors
The mouse podocyte MPC-5 cell line was originally provided by
Dr. Peter Mundel of Harvard Medical School and cultured as described
previously [13,14]. These cells express the podocyte markers nephrin,
podocin, synaptopodin andpodocalyxin. An expression vector encoding
full-length untagged mouse Sdc4 was purchased from Origene Inc.
(Rockville,MD, USA), andwas transfected into podocytes using Lipofec-
tamine 3000™ (Life Technologies, Grand Island, NY, USA) according to
the manufacturer's instructions. A panel of siRNAs targeting Sdc4, andnon-targeting control siRNAs were purchased from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA) and transfected into cells using Lipofecta-
mine 3000™.
2.2. Immunoblot analysis
Methods used for immunoblot analysis from podocyte lysates and
from various fractions of podocytes have been described previously
[13,14]. Brieﬂy, proteins from various podocyte preparations are sepa-
rated using 10% PAGE-SDS and then transferred to ﬁlters. These were
probed using primary antibodies, washed, incubated with horseradish
peroxidase-conjugated secondary antibodies, and visualized using
chemiluminescence. These experiments are carried out in triplicate
and quantiﬁed using densitometry using ImageJ™ software. Rabbit an-
tibodies against Sdc4 andβ3-integrinwere obtained fromAbcam (Cam-
bridge, MA, USA). The Sdc4 antibody recognizes the ectodomain of the
protein.
2.3. Cell-surface biotinylation assays to estimate steady-state surface ex-
pression of TRPC6 channels
These methods have been described in detail previously [13,14].
Brieﬂy, after various treatments, podocytes were exposed to a mem-
brane impermeable biotinylation reagent (Pierce Biotechnology,
Rockford, IL) to selectively label surface proteins. The reaction was
subsequently stopped, and cells were lysed. Surface proteins were
captured using immobilized streptavidin-agarose beads. A sample
of the initial cell lysate was kept for measurement of the total protein
abundance. Proteins in all of these fractions were then quantiﬁed by
immunoblot as described above using a polyclonal antibody against
TRPC6 purchased from Alomone Labs (Jerusalem, Israel).
2.4. Assay for nuclear abundance of NFATc1
NFATc1 was measured by immunoblot in whole cell lysates and in
podocyte nuclear extracts prepared using a kit from Active Motif Inc.
(Carlsbad, CA, USA). Antibodies to NFATc1 were from Active Motif Inc.
(Carlsbad, CA, USA). A mouse monoclonal anti-histone H1 (Millipore
Corporation) was used as a loading control for nuclei, and we used an
antibody against actin (Santa Cruz Inc., Santa Cruz, CA, USA) to normal-
ize for loading from total cellular lysates.
2.5. Assays for Rac1 and RhoA activation
Activities of RhoA and Rac1 were estimated using the G-LISA RhoA
Activation Assay Biochem Kit and theG-LISA Rac1 Activation Assay
Biochem Kit (Cytoskeleton, Inc., Denver, CO) according to the
manufacturer's directions. These kits are quantitative ELISA assays that
recognize only the active GTP-bound forms of RhoA and Rac1.
2.6. Assays for Sdc4 ectodomain shedding
Podocyteswere treatedwith 10 ng/ml TNF, or 5 ng/ml of recombinant
ADAM17, or sera from FSGS patients (see below), or cells were
transfected with Sdc4 expression vector using Lipofectamine 3000™ as
described above. Culturemediawere removed and 1 volume of trichloro-
acetic acid (TCA)was added to 4 volumes of culturemedia on ice. Follow-
ing incubation, the media were centrifuged at 13,000 RPM for 30 min at
4 °C. The resultingprotein pelletwaswashed three timeswith ice-cold ac-
etone, and allowed to dry in the air. The dried pellets were then re-
suspended by boiling in 2× SDS-PAGE sample buffer and analyzed by im-
munoblot using antibodies against Sdc4. The podocytes were detached
from the dish, pelleted, lysed and Sdc4 core protein and actin were quan-
tiﬁed by immunoblot to ensure that Sdc4was shed from equivalent num-
ber of cells in each sample. Bulk cytosolic ROS generation was quantiﬁed
using the OxiSelect™ Intracellular ROS Assay (Cell Biolabs Inc.) according
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dard ROS assays based on diacetylated 2′,7′-dichloroﬂuorescein, which
becomes trapped in cytosol, and then highly ﬂuorescent upon oxidation
in response to increased ROS generation.
2.7. Electrophysiology
These measurements were made from immortalized podocytes as
described in detail previously [10,12,14,31] using ﬁre-polished borosil-
icate glass microelectrodes (4–6 MΩ) and an Axopatch 1D ampliﬁer
(Molecular Devices, Foster City, CA). TRPC6 channels were activated
by bath application of 100 μM 1-oleoyl-2-acetyl-sn-glycerol (OAG), a
membrane permeable analog of DAG (Avanti Polar Lipids, Alabaster,
AL). Macroscopic currents were monitored during 2.5-s voltage ramps
from −80 mV to +80 mV, and currents at +80 mV were quantiﬁed
for statistical analysis. We have previously shown that these currents
are eliminated by TRPC6 knockdown and by application of agents ex-
pected to completely inhibit TRPC6 [10,12,14].
2.8. Confocal microscopy
Cells were ﬁxed by 30min exposure to 4% paraformaldehyde in PBS,
rinsed in PBS, blocked with 10% normal goat serum. Cells were exposed
to the primary antibodies rabbit anti-Sdc4 (1:1000) (Abcam) and
mouse anti-β3-integrin (1:1000) (Abcam) for 24 h at 4 °C. Note that
the cells were not permeabilized before exposing them to primary anti-
bodies. Appropriate secondary antibodies were from Invitrogen (Carls-
bad, CA, USA). All images were collected on an Olympus FV1000
confocal microscope using a Plan Apo N 60× 1.42NA oil-immersion
objective.
2.9. Acute PAN nephrosis model and urinalysis
These experiments were carried out according to a protocol ap-
proved by the University of Houston Institutional Animal Care and Use
Committee. Male Sprague–Dawley rats (150 g, purchased from Charles
River Laboratories,Wilmington,MA)were placed inmetabolic cages for
24 h to collect urine for baseline measurements of albumin, creatinine,
and Sdc4. The rats were then given a single i.p. injection of puromycin
aminonucleoside (PAN) (200 mg/kg) or a normal 0.9% saline vehicle.
After 10 days, the rats were returned to metabolic cages for 24-h urine
collection. Urine Sdc4 was measured using a Rat Sdc4 ELISA kit
(MyBioSource, Inc., San Diego, CA) according to manufacturer's instruc-
tions. Albumin was measured by ELISA using the Nephrat II™ kit
(Exocell, Philadelphia, PA). Creatinine was measured using a commer-
cial chemical assay (Creatinine Companion™, Exocell Inc.).
2.10. Recombinant proteins, drugs, other reagents
Recombinant TNF, recombinant Sdc4 ectodomain, and recombinant
ADAM17 were obtained from R&D Systems (Minneapolis, MN, USA).
Cilengitide was obtained from Selleck Chem (Houston, TX, USA). Cyclo-
sporine A (CsA) was purchased from Sigma-Aldrich (St. Louis, MO). The
cell-permeable NFAT inhibitor 11R-VIVIT (a peptide of the sequence
RRRRRRRRRRR-GGG-MAGPHPVIVITGPHEE) was purchased from
Millipore (Temecula, CA, USA). An inhibitor of Rac1 signaling, N6-[2-
[[4-(Diethylamino)-1-methylbutyl] amino]-6-methyl-4-pyrimidinyl]-
2-methyl-4,6-quinolinediamine trihydrochloride (NS-23766) was ob-
tained from Tocris Bioscience (Bristol, UK). A Rho inhibitor comprised
of amembrane-permeable formof exoenzymeC3 transferase from Clos-
tridium botulinumwas purchased from Cytoskeleton Inc. (Denver, CO).
Serum samples from patients with recurrent FSGS were provided by
Drs. Thomas Benzing and Henning Hagmann of the Department of
Medicine II at the University of Cologne, Germany. No information
that would allow identiﬁcation of these patients was provided. Serum
samples from one adult male patient were taken at a time when hepresented in relapse and later after this patient achieved a remission as
a result of intensive LDL apheresis therapy using a Miltenyi TheraSorb™
column (Miltenyi Biotec, Gladbach, Germany) with preabsorbed sheep
antibody against the B-100 component of LDL. Serum samples from two
other recurrent FSGS patients were only available from a single time
point. These samples have been stored at−80 °C.
2.11. Analysis of quantitative data
All immunoblots were analyzed by densitometry using ImageJ™. All
bar graphs are presented as unit-less fold-changes of treatments rela-
tive to the smallest value observed in any replicate of the control
group. All experiments were repeated 3–6 times. Biochemical data in
bar graphs are presented as mean ± standard deviation.
3. Results
We have conﬁrmed previous reports that Sdc4 regulates steady-
state surface expression of TRPC6 channels in immortalized podocytes
(MPC-5 cells) [15]. In initial experiments we observed a marked fall in
surface-abundance of TRPC6 after Sdc4 knockdown using siRNA, as
assessed by cell surface biotinylation assays (Fig. 1a). There was also a
consistent reduction in the total abundance of TRPC6 measured 48 h
after transfection with siRNA, but over this relatively short timescale
the increase in surface channels was more impressive than effects on
total abundance of the protein. Conversely, we observed that transient
over-expression of Sdc4 in immortalized podocytes increased steady-
state surface expression of TRPC6 (Fig. 1b), again as reported previously
[15].Wehave also observed that simply exposing podocytes to a recom-
binant form of the soluble Sdc4 ectodomain (20 ng/ml) for 24 h is sufﬁ-
cient to evoke robust mobilization of TRPC6 channels to the cell surface
(Fig. 1c). Using whole-cell recordings, we observed increased TRPC6
activation by 100 μM OAG in podocytes pretreated with the Sdc4
ectodomain for 24 h (Fig. 1d, e), consistent with effects of Sdc4
ectodomain on surface abundance of TRPC6.
In other cell types, Sdc4 occurs in association with a variety of other
proteins including various integrins [31,32]. This is also true in
podocytes, as we have observed that β3-integrin can be precipitated
from podocyte lysates using antibodies to Sdc4 (Fig. 2a). This indicates
that these two proteins reside in the same complex, although their in-
teractions could still be indirect. Moreover, there are portions of the
podocyte cell surface in which there is co-localization of β3-integrin
and Sdc4 as seen using confocal immunoﬂuorescence (Fig. 2b). In addi-
tion, we observed that treating podocytes with 20 ng/ml Sdc4
ectodomain for 24 h caused a marked increase in the total abundance
ofβ3-integrin in these cells (Fig. 2c). The role of integrins in Sdc4 signal-
ing in podocytes will be addressed further below. Previous studies have
shown that the Sdc4 core protein interacts with proteins such as ezrin
that characterize the foot process apical domains [33], but Sdc4 did
not interact with slit diaphragm proteins such as nephrin and TRPC6
[15]. In conﬁrmation of this earlier report, we have also observed that
Sdc4 does not co-immunoprecipitate with TRPC6 in cultured podocytes
(Fig. 2d).
Podocyte TRPC6 channels aremobilized to the cell surface in response
to reactive oxygen species (ROS) [10–14]. In this regard, we have ob-
served that exposing cultured podocytes to the Sdc4 ectodomain for
24 h causes a marked increase in the bulk cytoplasmic abundance of
ROS in these cells (Fig. 3a). TRPC6 activation in podocytes is reported to
drive changes in activity of various small GTPases [34,35] and transcrip-
tion factors such as NFATc1 [36, 37]. We observed that treatment with
the Sdc4 ectodomain caused a fall in RhoA activation (Fig. 3b), as has
been reported previously with overexpression of the full-length protein
[15]. In addition, we have observed that the Sdc4 ectodomain evoked an
increase in Rac1 activation (Fig. 3c). Sdc4 effects on small GTPases were
assessed by measuring the GTP-bound forms of these molecules in
podocyte lysates using quantitative ELISA assays. In addition, the Sdc4
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Fig. 1. Sdc4 modulates podocyte TRPC6 channels. (a) Knockdown of endogenous Sdc4 using siRNA reduces steady-state surface expression of TRPC6 in immortalized mouse podocytes.
Blots on the left are results of representative cell-surface biotinylation assay. Note substantial reduction of surface TRPC6, and total Sdc4 in cells transfectedwith siRNA targeting Sdc4 com-
pared to cells transfected with non-targeting siRNA. Bar graphs to the right show densitometric analyses of three repetitions of this experiment. In this and subsequent ﬁgures, bars rep-
resent mean ± standard deviation except as noted below. Ordinates represent fold changes in signal compared to control.(b) Overexpression of Sdc4 increases steady-state surface
expression of TRPC6. Representative cell-surface biotinylation assay and densitometric analysis is shown below the blot. (c) Exposing podocytes to recombinant Sdc4 ectodomain
(20 ng/ml) for 24 h caused a marked increase in steady-state surface expression of TRPC6. (d) Representative whole-cell recordings from podocytes showing cationic currents evoked
by 100 μM OAG and blockade of these currents by 50 μM La3+. Traces shown are of cationic currents recorded during application of voltage ramps (−80 mV to +80 mV over 2.5 s).
Note that cationic current in the presence of OAG is larger in the Sdc4-treated cell. (e) Summary of the fold increase in current at +80 mV evoked by OAG over baseline in control
cells and cells exposed to Sdc4 ectodomain for 24 h. This bar graph plots mean ± s.e.m. from 10 cells in each group. Asterisk indicates P b 0.05 by Student's unpaired t-test.
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clei isolated from cultured podocytes (Fig. 3d).
The effects of Sdc4 on surface expression of TRPC6 require outside-in
signaling through integrins.We established this using cilengitide (CGT),
an N-methylated cyclic RGD pentapeptide that binds speciﬁcally to αv
subunits of certain integrins and prevents their outside-in activation
by several different ligands [38]. We observed that the presence of
1 μM CGT in media markedly reduced effects of Sdc4 ectodomains on
surface expression of TRPC6 (Fig. 4a) and abolished Sdc4 effects on ex-
pression of β3-integrin (Fig. 4b). CGT by itself causes some stimulation
of basal TRPC6 trafﬁcking. This effectwasnoted but not investigated fur-
ther. CGT also reduced Sdc4 ectodomain effects on ROS generation, and
blocked modulation of RhoA and Rac1 activation, and translocation of
NFATc1 to the cell nucleus (Fig. 5).
Previous studies have shown that increased ROS generation is an im-
portant factor in increasing mobilization and activation of podocyte
TRPC6 channels, and indeed ROS are required in order to observe
TRPC6 activation by AngII [10,11], insulin [13], and P2Y receptor ago-
nists such as ATP [12]. Similarly, TRPC6 mobilization evoked by Sdc4
was abolished by pretreatment with TEMPOL, a membrane-permeable
mimic of superoxide dismutase (Fig. 6a). However, TRPC6 mobilization
was not affected by the calcineurin–NFATc1 pathway, as this effect of
Sdc4 persisted in the presence of the calcineurin inhibitor cyclosporine
A (Fig. 6b) or the cell-permeable NFATc1 inhibitor 11R-VIVIT [39]
(Fig. 6c). We also examine the possible contribution of small GTPases
to Sdc4 effects on surface levels of TRPC6. We observed that NSC-23766, a small-molecule inhibitor of Rac1, eliminated the increase in
surface TRPC6 evoked by Sdc-4 (Fig. 6d). To assess the role of RhoA,
we used a membrane permeable form of C3 transferase, which causes
ADP-ribosylation of RhoA, RhoB, and RhoC and thereby inhibits them.
We have previously shown that this reagent reduces surface expression
of large conductance Ca2+-activated K+ channels in podocytes [40].
We observed here that cell permeant C3 transferase was by itself sufﬁ-
cient to causemodest increases in surface abundance of TRPC6, and it is
worth noting that addition of Sdc4 on top of that did not cause any ad-
ditional increase (Fig. 6e). These data are consistent with a role for Rac1
activation, and possibly also RhoA inhibition, in Sdc4 modulation of
TRPC6.
The ectodomains of Sdc4 can be shed frommany different cell types
during various cell signaling cascades. We observed that exposing
mouse podocytes to 10 ng/ml of the pro-inﬂammatory cytokine tumor
necrosis factor (TNF) for 24 h caused an increase in the amount of
Sdc4 that could be detected in the culturemedium(Fig. 7a).Wehave re-
cently shown that TNF is a potentmodulator of the surface expression of
TRPC6 [41]. A similar effect was evoked by serum or plasma from pa-
tients with recurrent forms of focal and segmental glomerulosclerosis
(FSGS), which are thought to be triggered by circulating factors. In the
experiment in Fig. 7b, we cultured podocytes for 24 h in medium con-
taining serum from an adult FSGS patient sampled during relapse of
his disease, or in serum from the same patient taken shortly after inten-
sive apheresis therapy induced a remission of the disease (Fig. 7b). Con-
siderably greater Sdc4 ectodomain shedding from podocytes was
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served increased Sdc4 ectodomain shedding in response to sera from
two other recurrent FSGS patients (Fig. 7c), although in those cases
the only samples we could obtain were from patients in relapse. Thus,b)a)
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core protein (Fig. 7d).
The observation that Sdc4 ectodomain shedding is inducible from
podocytes raises the question ofwhether these proteins can be detected
in urine. To address this, we examined the acute puromycin amino-
nucleoside (PAN) model of albuminuria in Sprague–Dawley rats. This
agent is selectively taken up by podocytes where it is metabolized to
produce oxidative stress [42]. In the acute phase of PAN-evoked albu-
minuria there is effacement of podocyte foot processes that can be ob-
served in ultrastructural studies, and loss of some podocytes, but little
if any change on any other cell type [43]. Rats given a single i.p. injection
of PAN show an increase in 24-h urine albumin excretion (Fig. 8a).
There was also an increase in the urine Sdc4/creatinine ratio in PAN-
treated animals compared to saline-treated controls, and also compared
to what was observed in the same animals prior to PAN treatment
(Fig. 8b).
4. Discussion
The novel observations of the present study are (1) the soluble
ectodomains of Sdc4 can activate a wide range of signaling pathways
that surroundmobilization of TRPC6 channels to the surface of cultured
podocytes, including generation of ROS, modulation of small GTPases
and increased abundance of nuclear NFATc1; (2) exposure to Sdc4
ectodomain results in increased expression of β3-integrin subunits in
podocytes; (3) outside-in signaling through αv-containing integrins is
required for the full effects of Sdc4 ectodomains on TRPC6 and its sur-
rounding pathways in podocytes; (4) shedding of Sdc4 ectodomains
from podocytes is a regulated process that can be triggered by pro-inﬂammatory agents such as TNF, and (5) the ectodomain of Sdc4 can
be detected in urine and is increased there in a widely studied rat
model of podocyte disease. Some of the effects of the Sdc4 ectodomain
described here, including mobilization of TRPC6 channels and modula-
tion of RhoA, have been described previously after the Sdc4 core protein
was over-expressed in a differentmouse podocyte cell line [15], and our
observations with Sdc4 knockdown are identical to those reported in
that earlier study. Indeed, those workers observed that constitutive
Sdc4−/−mice do not express detectable TRPC6 channels in podocytes
or renal cortex, although TRPC3 and nephrin are still present, and
those animals are protected in albumin overload models of proteinuria
[15].
There is now considerable evidence that sustained hyperactivation
of podocyte TRPC6 channels can trigger glomerulosclerosis [4–7], and
therefore anything that can lead to increases in their steady-state ex-
pression on the podocyte surface and subsequent activation warrants
investigation. To some extent, TRPC6 trafﬁcking reﬂects the total cellu-
lar abundance of TRPC6, which over time is enhanced by calcineurin–
NFATc1 pathways [36,37]. In the present study we observed increased
nuclear NFATc1 after treatment with the Sdc4 ectodomain (Fig. 9).
TRPC6 trafﬁcking evoked by Sdc4 ectodomains is associatedwith in-
creased ROS generation in podocytes, and the effect of Sdc4 is blocked
by a ROS quencher. This oxidative mode of TRPC6 regulation was origi-
nally described in heterologous expression systems [44] and it underlies
mobilization of podocyte TRPC6 evoked by many different mediators,
including insulin [13], Ang II [10,11], P2Y agonists such as ATP [12], ele-
vated glucose [45] and even canonical lipid activators of TRPC6 such as
diacylglycerol [14] and 20-HETE (unpublished observations). As a result
of this process, oxidative stress in podocytes will inevitably be
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ute to podocyte detachment in an inﬂammatory milieu.
It has been proposed that one of the effects of Ca2+ inﬂux through
TRPC6 is an increase in the abundance of the active GTP-bound form
of RhoA, which is thought to be a secondary consequence of proteolytic
degradation of synaptopodin [34,35]. However, Liu et al. [15] observed0
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renal cortex, owing to activation of RhoGAP by the Sdc4 core protein,
even though TRPC6 is not detectable in the glomeruli of those animals.
This was also seen after Sdc4 knockdown in cultured podocytes [15],
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tion of Sdc4 ectodomain.We have extended those observations by show-
ing that Rho inhibition is by itself sufﬁcient to increase surface TRPC6 in
this cell line, and also that Sdc4 evokes an increase in Rac1 activation
which appears to be required for Sdc4 effects on TRPC6. The effects on
small GTPases could be seen even with relatively short exposures to
Sdc4 ectodomain (b1 h). It is of course possible that there are multiple
pools of TRPC6 in podocytes [9], and possibly also multiple pools of
Rac1 and RhoA, and that regulation is different depending on where in
the cell one looks.
We observed that the Sdc4 core protein in podocytes co-
immunoprecipitates with β3-integrin suggesting that they reside to-
gether in a larger complex (which need not imply a direct interaction).
Integrins can function as receptors and co-receptors for a variety of sol-
uble signaling factors [46,47], andwe hypothesized that integrinsmight
function as receptors or co-receptors for the Sdc4 ectodomain in
podocytes. We tested this hypothesis using cilengitide, a highly selec-
tive inhibitor of ligand-dependent outside-in activation of integrins
containing αv subunits [38]. Podocytes are reported to express αvβ1,
αvβ3 and αvβ5 integrins, which would be sensitive to this agent [48].
In the present study, we also observed increasedβ3-integrin expression
in response to Sdc4 ectodomain. Consistentwith our hypothesis, we ob-
served that cilengitide blocked all of the effects of Sdc4 ectodomain that
we have observed in podocytes, including the increased surface expres-
sion of TRPC6 channels, increased ROS generation, modulation of small
GTPases, and activation of NFATc1. In this regard, several antagonists of
outside-in integrin signaling have protective effects in animalmodels of
podocyte diseases, including diabetic nephropathy in pigs [49] and rats
[50], lipopolysaccharide-induced podocyte effacement [51], acute PAN
nephrosis [51], and the early stages of experimental glomerulonephritis
[52]. There is also evidence that constitutive activation ofαvβ3 integrins
in podocytes leads to albuminuria, glomerulosclerosis, and activation of
Rac1 [53]. Therefore, identiﬁcation of ligands that activate integrinsignaling in podocytes is signiﬁcant, and may provide insight into cir-
cumstances whereby those integrins become active.
Given that Sdc4 ectodomains are sufﬁcient to activate a variety of
deleterious pathways in podocytes, the question arises as to whether
podocytes are likely to encounter the soluble forms of these proteogly-
cans in vivo. Sdc4 ectodomains can be detected in serum and are mark-
edly increased during certain pathological conditions, such as in heart
failure, where circulating Sdc4 can reach 100 ng/ml [54]. It is not
known whether Sdc4 ectodomains would pass through the glomerular
ﬁlter, although their marked negative charge would certainly reduce
their permeability [55]. However, Sdc4 ectodomains can also be shed
from glomerular endothelial cells in response to TNF [16], as well as
from podocytes, as we show here. In addition, we have observed that
serum from three different patients with relapsed recurrent FSGS can
induce substantially greater Sdc4 ectodomain shedding than is seen
with serum taken from the same patient after remission was achieved.
These data suggest that Sdc4 ectodomains secreted within glomeruli
maymodulate podocyte behavior. ADAM17has been previously report-
ed to cause cleavage of Sdc4 resulting in ectodomain shedding [56], and
we observed here that it produces a similar effect on podocytes. In this
regard, ADAM17 transcripts aremarkedly increased throughout the glo-
merulus in minimal change disease and FSGS [57], and in diabetic ne-
phropathy [58], while its endogenous inhibitor, TIMP-3 [59] is reduced
in diabetic nephropathy [60]. Collectively, these observations suggest
that soluble Sdc4 ectodomains released within glomeruli could contrib-
ute to glomerular pathology. Consistent with this, we observed an in-
crease in urine concentrations of Sdc4 ectodomain in the acute PAN
nephrosis model in rats. This could occur as a result of increased shed-
ding from glomerular cells, or increased glomerular permeation of cir-
culating ectodomains. These results may suggest the possibility of
targeting metalloproteinase Sdc4 sheddases for therapy of glomerular
diseases, and of using urinary Sdc4 ectodomains as a biomarker for glo-
merular dysfunction.
5. Conclusions
We have shown that soluble Sdc4 ectodomains exert several effects
on podocyte signaling pathways that have been implicated in glomeru-
lar diseases, includingmobilization of TRPC6channels to the cell surface,
modulation of RhoA and Rac1, generation of ROS, and activation
NFATc1. The effects of Sdc4 ectodomains on podocytes require
outside-in signaling through αv-containing integrins. Finally, Sdc4
ectodomains can be shed from podocytes after exposure to the inﬂam-
matory cytokine TNF, or sera of patients with relapsed recurrent FSGS,
and is increased in urine in a rat model of podocyte disease.
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